Harris & Harris Group Notes Mersana's Second Milestone Payment in Fleximer ADC Collaboration With Endo Pharmaceuticals
January 14 2014 - 02:44PM
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in
transformative companies enabled by disruptive science, notes the
announcement by portfolio company, Mersana Therapeutics, Inc., that
it has achieved the second preclinical milestone in its
collaboration with Endo Pharmaceuticals. In 2012, Mersana and Endo
entered into a multi-target, oncology-focused partnership to
develop next-generation Fleximer antibody-drug conjugates (ADCs).
The collaboration between Mersana and Endo leverages Mersana's
proprietary conjugation technology, comprised of the Fleximer
polymer and a broad array of customizable linker chemistries for
attaching diverse, potent payloads to antibodies. Under the
terms of the agreement, Mersana is responsible for conducting
research and creating Fleximer-ADC development candidates with
antibodies provided by Endo. The rights to these ADCs have
been licensed to Endo in exchange for research funding, milestone
payments and royalties on worldwide net sales of any resulting ADC
products.
Mersana's press release may be viewed at
http://www.mersana.com/news-events/news-events-press-release-2014-01-09.php.
Detailed information about Harris & Harris Group and its
holdings can be found on its website at www.HHVC.com and on
Facebook at www.facebook.com/harrisharrisvc.
This press release may contain statements of a forward-looking
nature relating to future events. These forward-looking statements
are subject to the inherent uncertainties in predicting future
results and conditions. These statements reflect the Company's
current beliefs, and a number of important factors could cause
actual results to differ materially from those expressed in this
press release. Please see the Company's Annual Report on Form
10-K for the fiscal year ended December 31, 2012, as well as
subsequent filings, filed with the Securities and Exchange
Commission for a more detailed discussion of the risks and
uncertainties associated with the Company's business, including,
but not limited to, the risks and uncertainties associated with
venture capital investing and other significant factors that could
affect the Company's actual results. Except as otherwise required
by Federal securities laws, the Company undertakes no obligation to
update or revise these forward-looking statements to reflect new
events or uncertainties. The references to the websites
www.HHVC.com, www.Facebook.com, and www.mersana.com have been
provided as a convenience, and the information contained on such
websites is not incorporated by reference into this press
release. Harris & Harris Group is not responsible for the
contents of third party websites.
CONTACT: DOUGLAS W. JAMISON
TEL. NO. (212) 582-0900
180 Degree Capital (NASDAQ:TURN)
Historical Stock Chart
From Feb 2024 to Mar 2024
180 Degree Capital (NASDAQ:TURN)
Historical Stock Chart
From Mar 2023 to Mar 2024